---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-000620"
form_type: "8-K"
ticker: "GPCR"
cik: "0001888886"
company_name: "Structure Therapeutics Inc."
filed_at: "2026-01-05T23:59:59+00:00"
generated_at: "2026-05-16T11:43:29.281500+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Structure Therapeutics licenses GLP-1 patents to Genentech for $100M upfront

## Summary
- Gasherbrum Bio (Structure sub) grants non-exclusive license to Genentech/Roche for CT-996 GLP-1 RA.
- Genentech pays $100M one-time non-refundable fee within 30 days; plus low single-digit royalties.
- License covers patents distinct from aleniglipron; Structure's own GLP-1/dual agonist programs unaffected.
- Either party may terminate for uncured material breach; Gasherbrum can terminate if GNE challenges patents.

## SEC filing metadata
- accession: 0001104659-26-000620
- form_type: 8-K
- ticker: GPCR
- cik: 0001888886
- company_name: Structure Therapeutics Inc.
- filed_at: 2026-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/0001104659-26-000620-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/tm261919d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-000620
- JSON: https://secwatch.observer/filing/0001104659-26-000620.json
- Plain text: https://secwatch.observer/filing/0001104659-26-000620.txt

## Key facts
- Material Agreements
  Structure Therapeutics Inc. entered into GNE Agreement with Genentech, Inc. and F. Hoffmann-La Roche Ltd valued at $100 million (effective 2025-12-30).
  - Action: entry
  - Agreement: license
  - Counterparty: Genentech, Inc. and F. Hoffmann-La Roche Ltd
  - Value: $100 million
  - Effective: 2025-12-30
  source text: On December 30, 2025, Gasherbrum Bio, Inc. ("Gasherbrum"), a wholly-owned subsidiary of Structure Therapeutics Inc. (the "Company"), entered into an agreement (the "GNE Agreement") with Genentech, Inc. ("Genentech") and F. Hoffmann-La Roche Ltd ("Roche" and together with Genentech, "GNE") that was the culmination of discussions initiated by Genentech’s inquiry regarding the availability of a license to certain patents of Gasherbrum
  evidence_url: https://www.sec.gov/Archives/edgar/data/1888886/000110465926000620/0001104659-26-000620-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.